Bioresorbable Vascular Scaffold Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

Bioresorbable vascular scaffolds are implants used during percutaneous coronary intervention to restore blood flow in vessels affected by atherosclerotic plaque, after which the scaffold is metabolised by the body over months to a few years. The category evolved from earlier bare-metal and durable polymer drug-eluting stents and is now positioned as the next generation of coronary intervention. The global market is valued at approximately USD 0.67 billion in 2025 and is forecast to grow at a CAGR of 9.17%, reaching close to USD 1 billion by the early 2030s.

• •2025 market size: ~USD 0.67 billion; forecast CAGR of 9.17%
• •Second-generation BVS devices use improved poly-L-lactic acid and other bioresorbable polymers with controlled drug release
• •Temporary scaffold design allows vessel remodeling and reduces late-stage complications linked to permanent metallic stents

The steady rise in coronary artery disease cases, driven by aging populations and lifestyle-related risk factors such as diabetes, obesity and hypertension, is expanding the addressable patient pool for BVS. Technological progress in resorbable polymer chemistry and thinner-strut device designs is improving deliverability, healing and long-term safety, which is rebuilding physician confidence after early-generation product concerns. Favourable reimbursement policies and expanding cath-lab capacity in emerging economies are further accelerating adoption.

• •Rising global prevalence of coronary artery disease boosts procedure volumes
• •Advances in polymer science and thinner-strut scaffolds improve clinical outcomes over first-generation devices
• •Growing adoption in ambulatory surgical centres and specialty cardiac centres beyond traditional hospital cath-labs

The market is typically segmented by product type (synthetic and biological scaffolds), material (polymer-based and metallic bioresorbable alloys), application (coronary artery disease and peripheral artery disease), and end user (hospitals, cardiac centres, and ambulatory surgical centres). Polymer-based platforms dominate today because of their predictable degradation profiles and established manufacturing base. North America leads in revenue share owing to high procedure volumes and early technology uptake, while Asia-Pacific is the fastest-growing region as China and India invest in cath-lab infrastructure.

• •Polymer-based scaffolds hold the largest material share; metallic alloys remain a smaller, niche segment
• •Hospitals are the leading end user, with cardiac centres and ambulatory surgical centres growing quickly
• •North America leads current revenue; Asia-Pacific is the fastest-growing regional market

What are the recent trends and outlook?

The pipeline is shifting toward thinner-strut scaffolds with shorter resorption windows, designed to balance mechanical support with more natural vessel healing and to address the late-thrombosis concerns associated with first-generation devices. Magnesium- and zinc-based metallic alloys are being explored as alternatives to traditional PLLA platforms for improved deliverability. With rising procedure volumes in emerging markets and continued clinical evidence supporting resorbable devices, the market is expected to maintain mid- to high-single-digit growth through the early 2030s.

• •Thinner-strut designs and shorter resorption periods are the main engineering focus
• •Magnesium- and zinc-based bioresorbable alloys are emerging as polymer alternatives
• •Clinical trial read-outs and expanding indication coverage are expected to be the key catalysts over the next 5-7 years